Clinical trials: Gliosarcoma of Brain
Brain and Central Nervous System Tumors
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00275067
- Testing
- arsenic trioxide, temozolomide, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00021307
- Testing
- carboplatin, temozolomide
- Sponsor
- Fox Chase Cancer Center
Glioblastoma, Gliosarcoma
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Background: Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But the tumors almost always recur.
- Conditions
- Glioblastoma, Gliosarcoma, Malignant Glioma
- Trial name
- NCT04817254
- Testing
- TMZ, ipilimumab 3mg/kg, Nivolumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as motexafin gadolinium may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00022256
- Testing
- motexafin gadolinium, radiation therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002753
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma.
- Trial name
- NCT00003842
- Testing
- interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barrett Cancer Center
Recurrent Adult Brain Tumor
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00362921
- Testing
- Gliadel wafers in combination with O6-benzylguanine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
RATIONALE: Imaging procedures that use aminolevulinic acid (ALA) may help find and diagnose residual tumor in participants with grade IV malignant astrocytoma who are undergoing surgery to remove the tumor.
- Trial name
- NCT00752323
- Testing
- aminolevulinic acid, Surgical Resection
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Andrew Sloan, MD
Pediatric Solid Tumor, Pediatric Lymphoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment…
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG
- Trial name
- CLOVER-2 (NCT03478462)
- Testing
- CLR 131
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.